In a statement to WIRED, a Lilly spokesperson Niki Biro noted that, given its effectiveness, retatrutide is currently being targeted to those with high BMI or with obesity-related complications that require a high degree of weight loss, where the clinical need may be greater. Biro also cautions that retatrutide is an investigational molecule that is legally available only to participants in Lillys clinical trials
Rizzon, P., Biasco, G., Di Biase, M., Boscia, F., Rizzo, U., Minafra, F., Bortone, A., Siliprandi, N., Procopio, A., Bagiella, E., and
One tested sample turned out to be nothing more than sugar alcohol
Meaningful weight loss becomes visible after two to four weeks of consistent medication use and dietary adherence
Pathol Res Pract 177, 1321